Ethan Canty1, Benjamin Carnahan1, Tara Curley2, Emily Anususinha2, Rana F Hamdy2,3, Jessica E Ericson4. 1. From the Penn State College of Medicine, Hershey, Pennsylvania. 2. Division of Infectious Diseases, Children's National Hospital, Washington, DC. 3. Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC. 4. Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.
Abstract
BACKGROUND: Clinical implications of reduced vancomycin susceptibility (RVS) among pediatric Staphylococcus aureus bloodstream infections are unknown. METHODS: We identified all children at 2 children's hospitals with ≥1 blood culture positive for S. aureus. We compared patient and clinical factors for RVS and non-RVS infections using Wilcoxon rank-sum and chi-squared tests. Treatment failure and the duration of bacteremia for RVS versus non-RVS and for methicillin-resistant Staphylococcus aureus (MRSA) versus methicillin-susceptible Staphylococcus aureus (MSSA) infections were compared using multivariable logistic and Poisson regressions, respectively. For MRSA infections, the association of empiric vancomycin monotherapy with treatment failure was assessed using multivariable logistic regression. RESULTS: RVS was present in 72% (309/426) of cases. No patient or infection characteristics, including methicillin resistance, were associated with RVS. RVS was associated with an increased duration of bacteremia compared with non-RVS infections, aIRR = 1.15 (95% confidence interval: 1.02-1.30). The odds of treatment failure was similar for RVS and non-RVS infections, aOR = 1.04 (0.62-1.74). In contrast, MRSA infections were more likely to have treatment failure than MSSA infections, aOR = 3.03 (95% confidence interval: 1.84-5.00). For MRSA infections, empiric vancomycin monotherapy was associated with an increased odds of treatment failure compared with non-vancomycin or combination anti-MRSA antibiotics, aOR = 3.23 (1.12-9.26). CONCLUSIONS: RVS was common and was associated with a longer duration of bacteremia but not with treatment failure. Treatment failure was more common for MRSA than for MSSA bloodstream infections. Empiric vancomycin monotherapy increased the odds of treatment failure for MRSA infections.
BACKGROUND: Clinical implications of reduced vancomycin susceptibility (RVS) among pediatric Staphylococcus aureus bloodstream infections are unknown. METHODS: We identified all children at 2 children's hospitals with ≥1 blood culture positive for S. aureus. We compared patient and clinical factors for RVS and non-RVS infections using Wilcoxon rank-sum and chi-squared tests. Treatment failure and the duration of bacteremia for RVS versus non-RVS and for methicillin-resistant Staphylococcus aureus (MRSA) versus methicillin-susceptible Staphylococcus aureus (MSSA) infections were compared using multivariable logistic and Poisson regressions, respectively. For MRSA infections, the association of empiric vancomycin monotherapy with treatment failure was assessed using multivariable logistic regression. RESULTS: RVS was present in 72% (309/426) of cases. No patient or infection characteristics, including methicillin resistance, were associated with RVS. RVS was associated with an increased duration of bacteremia compared with non-RVS infections, aIRR = 1.15 (95% confidence interval: 1.02-1.30). The odds of treatment failure was similar for RVS and non-RVS infections, aOR = 1.04 (0.62-1.74). In contrast, MRSA infections were more likely to have treatment failure than MSSA infections, aOR = 3.03 (95% confidence interval: 1.84-5.00). For MRSA infections, empiric vancomycin monotherapy was associated with an increased odds of treatment failure compared with non-vancomycin or combination anti-MRSA antibiotics, aOR = 3.23 (1.12-9.26). CONCLUSIONS: RVS was common and was associated with a longer duration of bacteremia but not with treatment failure. Treatment failure was more common for MRSA than for MSSA bloodstream infections. Empiric vancomycin monotherapy increased the odds of treatment failure for MRSA infections.
Authors: Fernando Docobo-Pérez; Rafael López-Rojas; Juan Domínguez-Herrera; Manuel E Jiménez-Mejias; Cristina Pichardo; José Ibáñez-Martínez; Jerónimo Pachón Journal: J Antimicrob Chemother Date: 2012-04-24 Impact factor: 5.790
Authors: Natasha E Holmes; John D Turnidge; Wendy J Munckhof; James O Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Wei Gao; Keryn J Christiansen; Geoffrey W Coombs; Paul D R Johnson; Benjamin P Howden Journal: J Infect Dis Date: 2011-08-01 Impact factor: 5.226
Authors: L E López-Cortés; C Velasco; P Retamar; M D del Toro; J Gálvez-Acebal; M de Cueto; I García-Luque; F J Caballero; A Pascual; J Rodríguez-Baño Journal: J Antimicrob Chemother Date: 2015-05-28 Impact factor: 5.790
Authors: Andrew E Simor; Linda Pelude; George Golding; Rachel Fernandes; Elizabeth Bryce; Charles Frenette; Denise Gravel; Kevin Katz; Allison McGeer; Michael R Mulvey; Stephanie Smith; Karl Weiss Journal: Infect Control Hosp Epidemiol Date: 2016-01-19 Impact factor: 3.254
Authors: Jiraganya Bhongsatiern; Chris Stockmann; Jessica K Roberts; Tian Yu; Kent E Korgenski; Michael G Spigarelli; Pankaj B Desai; Catherine M T Sherwin Journal: Ther Drug Monit Date: 2015-12 Impact factor: 3.681
Authors: Joshua T Thaden; Jessica E Ericson; Heather Cross; Stephen P Bergin; Julia A Messina; Vance G Fowler; Daniel K Benjamin; Reese H Clark; Christoph P Hornik; P Brian Smith Journal: Pediatr Infect Dis J Date: 2015-11 Impact factor: 3.806
Authors: Edward J A Douglas; Abdulaziz H Alkhzem; Toska Wonfor; Shuxian Li; Timothy J Woodman; Ian S Blagbrough; Maisem Laabei Journal: Front Microbiol Date: 2022-08-22 Impact factor: 6.064